Gavestinel

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Gavestinel
Gavestinel.svg
Clinical data
Synonyms GV-150,526A
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C18H12Cl2N2O3
Molar mass 375.205 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Gavestinel (GV-150,526) was an investigational drug developed by GlaxoSmithKline for acute intracerebral hemorrhage, which in 2001 failed to show an effect in what was at the time, the largest clinical trial in stroke that had been conducted.[1][2]

Gavestinel is an NMDA antagonist, binding selectively to the glycine site on the NMDA receptor complex, rather than the glutamate site many NMDA antagonists bind to.[3][4][5]

Pharmacology and Toxicology[edit]

N-methyl-D-aspartate (NMDA) receptors are amino acid receptors, overstimulation to which lead to increased intracellular Ca2+ level, and become deleterious to neural cell. In ischaemic or hypoxic conditions such as stroke, the concentration of glutamate in synaptic clefts is increased, and continuously stimulates NMDA receptors. Gavestinel was synthesized by substituting indole-2-carboxylate at the C-3 position with an unsaturated lateral side chain. It binds to NMDA receptor on the glycine site with high affinity, selectivity and a broad time window efficacy, thus gains interests in testing its efficacy in treating stroke. In pre-clinical studies, gavestinel showed no significant side effects on memory, learning, and cardiovascular system, side effects that are very common in NMDA antagonists.[6]

Clinical Studies[edit]

In phase ΙΙ clinical studies to investigate safety, tolerability of gavestinel, no findings showed that it had significant side effects. The dose determined in phase ΙΙ trials was selected for further phase ΙΙΙ trials.[7]Later, however, in two large phase ΙΙΙ trials, gavestinel showed no efficacy in treating ischemic stroke.[8]

References[edit]

  1. ^ Elda Hauschildt for PSL. 3 April, 2001 No Benefit From Early Gavestinel Therapy For Acute Stroke Patients A DGReview of :"Glycine Antagonist in Neuroprotection for Patients With Acute Stroke GAIN Americas: A Randomized Controlled Trial" Journal of the American Medical Association (JAMA)
  2. ^ Susan Jeffrey for Medscape News. April 04, 2001 GAIN Americas trial again shows no benefit from neuroprotectant agent in stroke
  3. ^ Chopra B, Chazot PL, Stephenson FA. Characterization of the binding of two novel glycine site antagonists to cloned NMDA receptors: evidence for two pharmacological classes of antagonists. British Journal of Pharmacology. 2000 May;130(1):65-72. PMID 10780999
  4. ^ Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 2002 Oct;1(6):383-6. PMID 12849400
  5. ^ Hoyte L, et al The rise and fall of NMDA antagonists for ischemic stroke. Curr Mol Med. 2004 Mar;4(2):131-6. PMID 15032709
  6. ^ Bordi, F., Mugnaini, M., Terron, A., Barnaby, R., & Reggiani, A. (2000). GV150526: a neuroprotective agent. CNS Drug Reviews, 6(2), 135-152.
  7. ^ Dyker, A. G., & Lees, K. R. (1999). Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke. Stroke, 30(5), 986-992.
  8. ^ Haley, E. C., Thompson, J. L., Levin, B., Davis, S., Lees, K. R., Pittman, J. G., ... & Sacco, R. L. (2005). Gavestinel Does Not Improve Outcome After Acute Intracerebral Hemorrhage An Analysis From the GAIN International and GAIN Americas Studies. Stroke, 36(5), 1006-1010.